High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
about
Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancerMultilevel omic data integration in cancer cell lines: advanced annotation and emergent properties.curatedOvarianData: clinically annotated data for the ovarian cancer transcriptomeInferring tumour purity and stromal and immune cell admixture from expression dataDegreeCox - a network-based regularization method for survival analysisMás-o-menos: a simple sign averaging method for discrimination in genomic data analysis.Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites.Metabolic profiling and novel plasma biomarkers for predicting survival in epithelial ovarian cancer.The prediction models for postoperative overall survival and disease-free survival in patients with breast cancerMolecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypesConnecting prognostic ligand receptor signaling loops in advanced ovarian cancer.OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.Differential antigen expression profile predicts immunoreactive subset of advanced ovarian cancersExpression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high-grade serous ovarian cancer.Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis.Molecular characterization of an intact p53 pathway subtype in high-grade serous ovarian cancer.Screening of feature genes of the ovarian cancer epithelia with DNA microarrayA multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinomaThe homeoprotein DLX4 controls inducible nitric oxide synthase-mediated angiogenesis in ovarian cancer.Network-based survival-associated module biomarker and its crosstalk with cell death genes in ovarian cancer.Integrative network analysis for survival-associated gene-gene interactions across multiple genomic profiles in ovarian cancer.Leveraging global gene expression patterns to predict expression of unmeasured genesPrognosis of treatment response (pathological complete response) in breast cancer.Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples.AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer.Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients.MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.Genetic and molecular changes in ovarian cancer.Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survivalPredicting time to ovarian carcinoma recurrence using protein markers.Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancerSingle-sample expression-based chemo-sensitivity score improves survival associations independently from genomic mutations for ovarian cancer PatientsPROGgene: gene expression based survival analysis web application for multiple cancers.Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes.Separate enrichment analysis of pathways for up- and downregulated genes.Evolutionary Origins of Cancer Driver Genes and Implications for Cancer Prognosis.Identifying prognostic signature in ovarian cancer using DirGenerankPersonalized dynamic prediction of death according to tumour progression and high-dimensional genetic factors: Meta-analysis with a joint model.Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis
P2860
Q26859166-B7AFC749-749D-4EDE-BCB9-54B22E9218F9Q30590335-C7061219-CE95-4DCD-B1C3-C0AC24CF92A8Q30611147-D58258AA-1506-4144-9ADD-8ACE597B2A2CQ30674996-8170DB54-B64B-42D5-B69D-5694A1E47716Q30835679-6C695A0A-B13C-430D-84CB-D7FF39F8AC59Q30838620-6CB8F7FD-5240-4CBB-89CF-830AF63274BFQ33748623-E19C85E7-1580-45DF-A3E3-44ED06DC3928Q33762042-5CD68FFD-1443-4640-BCFA-C320F1568D99Q33891155-73EC410E-B55B-4375-9CC8-B5B5A3A1BA31Q34199368-3047D8A0-1231-41B3-A5A4-ED93F548FE32Q34224414-28F94FDA-0584-415C-BD2D-7B10EE2F9906Q34447404-8F5A2CEE-2FA8-4CB9-B48D-3E1EA62F66F5Q34472941-E17A1B6D-C8D7-4641-B4B3-D58DBEFD244BQ34491120-C306FE30-48F2-4182-A184-7A846BE53A5AQ34514528-EA14CE85-81DB-453C-986F-69A99706D216Q34612419-B9AAB3BE-0A2A-4778-9071-EFF8EC5D5A83Q34759643-9D328331-9AD9-4D9A-822E-05B5BCCA1C4EQ34941883-EA0C37E9-4D66-4899-A4D1-EF6F4EAC4D43Q35595273-2FB7D761-CC83-4578-88E2-04F1898A2BBCQ35769650-71E382E5-52BF-4F61-A3BF-086AF1075F08Q35817496-4FFD4DEB-1A4A-4FDE-AC52-60AC5D851124Q35868350-769C550A-FC77-4492-9841-A5B6694834D0Q35971135-4FA36CCF-7F11-4C67-AF46-9A74A0493FFBQ36087199-E1A147E2-BF6E-403D-9DBE-855AD3EED63FQ36104522-D1F7C03C-3201-4C48-B03D-F9C8BAD611EAQ36182116-96487F41-0C2C-44D9-BB09-E97E8FA99EDCQ36586093-D588B1A4-D8D6-4FE3-83B6-30D27706A236Q37094076-B531D780-066F-4A55-B6DA-BFD1D558316DQ37109818-96645C59-8998-4D04-8006-CCCE2F95FBE9Q37123908-B365995E-81F6-4219-8B8C-1B971625665BQ37174032-691874DC-72D5-4B56-8C00-62F6EAD03EEAQ37211342-837B1B83-C1D4-465B-828C-75EAD8F4594EQ37420447-169E0795-C2C4-4442-A025-C56F9337C2DAQ37430771-DE30F2ED-1349-4935-8813-8FD0B3C20711Q37485636-DF7A6D8F-386D-46CE-A2AB-95698F430B6BQ37507799-E5F18752-272C-4C01-AE2D-278D7F1F3D4CQ38679257-968362BA-E217-4D15-981A-D48C748E3543Q38725310-2487EA96-A5CD-46AE-9684-5BAE8BB32862Q39019006-238FC264-32F4-4A04-AC5C-814EC4FBAC52Q39281286-514E2012-B193-4D40-B4B4-87D2493AA62B
P2860
High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
High-risk ovarian cancer based ...... antigen presentation pathway.
@en
type
label
High-risk ovarian cancer based ...... antigen presentation pathway.
@en
prefLabel
High-risk ovarian cancer based ...... antigen presentation pathway.
@en
P2093
P50
P1476
High-risk ovarian cancer based ...... f antigen presentation pathway
@en
P2093
Aikou Okamoto
Daichi Shigemizu
Etsuko Miyagi
Haruko Iwase
Hideaki Masuzaki
Hidetaka Katabuchi
Hiroaki Itamochi
Hiroyuki Fujiwara
Hiroyuki Seki
Hisaya Fujiwara
P304
P356
10.1158/1078-0432.CCR-11-2725
P407
P577
2012-01-12T00:00:00Z